Artiva Biotherapeutics (ARTV) Other Non Operating Income (2023 - 2026)
Artiva Biotherapeutics (ARTV) posted quarterly Other Non Operating Income of $2000.0 for Q1 2026, up 150.0% year-over-year from $800.0 in Q1 2025, and up 200.0% quarter-over-quarter from -$2000.0 in Q4 2025.
Powered by 
Analysis
Artiva Biotherapeutics (ARTV) Other Non Operating Income (2023 - 2026) Analysis & Trends
Artiva Biotherapeutics (ARTV) has reported Other Non Operating Income for 4 consecutive years, with $2000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income rose 150.0% year-over-year to $2000.0; the TTM figure through Mar 2026 stood at -$8000.0 (up 99.17% YoY), while the FY2025 annual figure was -$14000.0, down 108.92% from the prior year.
- Other Non Operating Income climbed to $2000.0 in Q1 2026 per ARTV's latest filing, from -$2000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $1.1 million in Q4 2023 and bottomed at -$977000.0 in Q3 2024.
- Historically, Other Non Operating Income has averaged $28250.0 across 4 years, with a median of $0.0 in 2025.
- Annual changes were most pronounced in 2024 — Other Non Operating Income sank 2054.0% — and 2026, when it surged 150.0%.
- Artiva Biotherapeutics' Other Non Operating Income stood at $1.1 million in 2023, then sank by 100.46% to -$5000.0 in 2024, then soared by 60.0% to -$2000.0 in 2025, then surged by 200.0% to $2000.0 in 2026.
- Business Quant data shows ARTV's Other Non Operating Income at $2000.0 in Q1 2026, -$2000.0 in Q4 2025, and -$3000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Artiva Biotherapeutics | 441.23 Mn | 441.23 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,000.00 |
| Mar 31, 2026 | 2,000.00 |
| Dec 31, 2025 | -2,000.00 |
| Sep 30, 2025 | -3,000.00 |
| Jun 30, 2025 | -5,000.00 |
| Mar 31, 2025 | -4,000.00 |
| Sep 30, 2024 | -977,000.00 |
| Jun 30, 2024 | -2.35 Mn |
| Mar 31, 2024 | -268,000.00 |
| Dec 31, 2023 | 3.08 Mn |
| Sep 30, 2023 | 50,000.00 |
| Jun 30, 2023 | 31,000.00 |